Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03851276
Other study ID # ECRI-12
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date June 28, 2019
Est. completion date March 30, 2020

Study information

Verified date December 2019
Source ECRI bv
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment. Surgical revascularization strategy and treatment planning will be solely based on MSCT (with FFRCT) without knowledge of the anatomy defined by conventional cine-angiography.


Description:

The CABG-REVOLUTION study is an investigator-initiated single-arm, multicentre, prospective study for patients with 3-vessel disease (with or without left-main involvement) referred to CABG treatment. Surgical revascularization strategy and treatment planning will be solely based on MSCT (with FFRCT) without knowledge of the anatomy defined by conventional cine-angiography.

One clinical follow-up visit including MSCT acquisition will be performed at 30 days after bypass surgery in order to assess graft patency and adequacy of the revascularization with respect to the surgical planning based on non-invasive imaging.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 30, 2020
Est. primary completion date March 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient referred to CABG treatment (as assessed by 'conventional Heart Team');

2. Patients with at least 1 stenosis (visually determined de novo lesions with =50% DS) in all 3 major epicardial territories (LAD and/or side branch, CX and/or side branch, RCA and/or side branch) supplying viable myocardium with or without left main involvement;

3. Patients with hypoplastic right coronary artery (RCA) with absence of descending posterior and presence of a lesion in the LAD and circumflex (CX)territories may be included in the trial as a 3vessel disease equivalent. Ostial LAD plus ostial left circumflex artery (LCX) may be included in the trial as a Left Main equivalent

4. Distal vessel size should be at least 1.5 mm in diameter as visually assessed in diagnostic angiogram;

5. Patient with silent ischemia, chronic stable angina or stabilized acute coronary syndromes with normalized (stable or decreasing) cardiac biomarker values Note: For patients showing elevated Troponin (cTn) (e.g. non-STEMI patients) at baseline (within 24h pre-CABG) an additional blood sample must be collected prior to the CABG procedure to confirm that: • hs-cTn or Troponin I or T levels are stable, i.e. the value should be within 20% range of the value found in the first sample at baseline, or have dropped • CK-MB and CK levels are within normal range If hs-cTn or Troponin I or T levels are stable or have dropped, or the Creatine kinase-MB (CK-MB) and Creatine kinase (CK) levels are within normal ranges, and the ECG is normal, the patient may be included in the study.

6. All anatomical SYNTAX Scores are eligible;

7. Patient amenable to a MSCT coronary angiography (e.g. no claustrophobia, high heartrate not amenable to beta-blockers, poor renal function, etc., up to discretion of investigator);

8. Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site;

9. The patient agrees to the 1-month follow-up visit including a MSCT coronary angiography.

Exclusion Criteria:

1. Under the age of 18 years;

2. Unable to give Informed Consent;

3. Known pregnancy at time of enrollment. Female of childbearing potential i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause). Female who is breastfeeding at time of enrollment;

4. Prior percutaneous coronary intervention (PCI) or CABG; history of coronary stent implantation;

5. Evidence of evolving or ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice);

6. Known renal insufficiency (e.g. serum creatinine >2.5mg/dL, or creatinine clearance =30 mL/min), or subject on dialysis, or acute kidney failure (as per physician judgment);

7. Concomitant cardiac valve disease requiring surgical therapy (reconstruction or replacement) and/or aneurysmectomy;

8. Single or two-vessel disease (at time of the conventional Heart Team consensus);

9. Non-graftable distal bed in >1 vessel as assessed by the surgeon based on conventional angiography;

10. Atrial fibrillation or significant arrhythmias;

11. Known allergy to iodinated contrast;

12. A Body Mass Index (BMI) of 35 or greater;

13. Currently participating in another trial and not yet at its primary endpoint.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Multi-sliced computed tomography (MSCT)
Surgery planning done based solely on MSCT.

Locations

Country Name City State
Belgium University Hospital of Brussels Brussels
Germany University Hospital of Jena Jena
Italy Centro Cardiologico Monzino Milan
Switzerland University Hospital of Zurich Zürich

Sponsors (3)

Lead Sponsor Collaborator
ECRI bv GE Healthcare, HeartFlow, Inc.

Countries where clinical trial is conducted

Belgium,  Germany,  Italy,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients in the intention to treat (ITT) population for whom CABG planning and execution was based solely on MSCT. 2 weeks after enrollment
Primary Number of graft/anastomoses for which graft/anastomosis stenosis (=50%DS - 99%DS) or occlusion (100%DS) occurred as percentage of the total number of intra graft/anastomoses. 1 month after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Recruiting NCT05786131 - Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI N/A
Recruiting NCT06168305 - Safety and Effectiveness of GENOSS DES in Patients With Multivessel Coronary Artery Disease
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Completed NCT01881555 - Functional Testing Underlying Coronary Revascularisation N/A
Not yet recruiting NCT06400290 - Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina N/A
Active, not recruiting NCT01621438 - Clinical Implication of 3-vessel Fractional Flow Reserve (FFR) N/A
Not yet recruiting NCT06378775 - Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery N/A
Completed NCT05125367 - Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease
Completed NCT01947439 - Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI N/A
Recruiting NCT05333068 - COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events N/A
Completed NCT02813473 - SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
Recruiting NCT05698719 - Validation of vFFR as Compared to FFR to Guide Revascularization of Non-culprit Lesions in STEMI Patients
Completed NCT01399736 - Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. N/A
Not yet recruiting NCT01311323 - Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease N/A
Completed NCT00818792 - Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease Phase 2
Completed NCT01199419 - Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP N/A
Completed NCT04743154 - In-hospital Versus After-discharge Complete Revascularization N/A
Terminated NCT02334826 - Revascularization With BVS or CABG in Patients With Advanced CAD Phase 4